Study of the CD40 Agonistic Monoclonal Antibody APX005M

Clinical trial NCT02482168 · COMPLETED

Trial details

NCT number: NCT02482168
Sponsor: Apexigen America, Inc.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Cancer NSCLC Melanoma Urothelial Carcinoma MSI-H Head and Neck Cancer

Start date: 2015-05-01
Primary completion: 2018-06-13
Enrollment: 43

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.